ITEMS IN AFP WITH KEYWORD:

Diabetes

Aug 1, 2018 Issue
Type 1 Diabetes: Management Strategies [Article]

Patients with type 1 diabetes should maintain tight glycemic control to prevent complications. Frequent self-monitoring of blood glucose levels leads to improved A1C levels. Insulin administration via multiple daily injections or an insulin pump is effective. Physicians should educate patients about lifestyle management, recognition of hypoglycemia, and proper care during sick days.


Aug 1, 2018 Issue
Diabetes: ADA Releases Revised Position Statement on Standards of Medical Care [Practice Guidelines]

Because the evidence regarding medical care for persons with diabetes mellitus continues to evolve, the American Diabetes Association (ADA) annually updates its standards. In addition, starting in 2018, the ADA will also periodically update its guidance online if warranted.


May 1, 2018 Issue
Top 20 Research Studies of 2017 for Primary Care Physicians [Article]

The latest installment of the top 20 research studies for primary care physicians includes studies on cardiovascular disease and hypertension, infections, diabetes mellitus, musculoskeletal problems, and cancer screening, among other topics. The five highest-rated practice guidelines are also summarized.


Apr 1, 2018 Issue
DPP-4 Inhibitors and GLP-1 Receptor Agonists for Prevention or Delay of Type 2 Diabetes Mellitus and Associated Complications [Cochrane for Clinicians]

There is only limited-quality evidence that at-risk patients taking GLP-1 receptor agonists are less likely to progress to diabetes (number needed to treat [NNT] = 23). Serious adverse events were more likely in patients taking GLP-1 receptor agonists than in patients taking placebo (number needed to harm [NNH] = 42).


Feb 15, 2018 Issue
Diabetes Education and Glycemic Control [FPIN's Clinical Inquiries]

Counseling by a diabetes educator or a team of educators delivered in a variety of formats may reduce A1C levels by 0.2% to 0.8% compared with usual care alone. Diabetes educators should be considered for patients who have higher baseline A1C levels (8% to 9%) because this group had greater improvem...


Jan 1, 2018 Issue
Type 2 Diabetes Mellitus: Outpatient Insulin Management [Article]

In patients with type 2 diabetes mellitus, insulin may be used to augment therapy with oral glycemic medications or as insulin replacement therapy. Insulin regimens should be adjusted every three or four days until self-monitoring of blood glucose targets are reached. Goals should be individualized.


Dec 15, 2017 Issue
Home Glucose Monitoring Offers No Benefit to Patients Not Using Insulin [POEMs]

Home glucose monitoring of patients in primary care does not improve A1C scores or quality of life over one year in patients who are not taking insulin.


Dec 1, 2017 Issue
Hyperosmolar Hyperglycemic State [Article]

Although this life-threatening emergency commonly affects adults with type 2 diabetes mellitus, its incidence is increasing in children. Read the latest evidence on causes, risk factors, and complications, and get a treatment algorithm from the American Diabetes Association.


Nov 15, 2017 Issue
Glucose Management in Hospitalized Patients [Article]

Challenges to glucose control in hospitalized patients with type 2 diabetes mellitus include determining blood glucose targets, judicious use of oral diabetes medications, and implementing appropriate insulin regimens. Home oral diabetes medications should be continued in the absence of contraindications. Insulin dosing is based on patient factors, such as current oral intake, comorbidities, baseline diabetic control, and experience with prior insulin therapy. Sliding scale insulin regimens are not recommended.


Oct 15, 2017 Issue
Newer Oral Hypoglycemics Do Not Increase or Decrease Mortality [POEMs]

This seems like a strange question considering that the goal is to decrease mortality with drug therapy. Nevertheless, this study showed that the new kids on the diabetes block—exenatide (Byetta), dulaglutide (Trulicity), sitagliptin (Januvia), saxagliptin (Onglyza), and others—do not increase mortality, even in patients with cardiovascular risk.


Pages: 1 2 3 4 5 6 7 8 9 10 ... 15 Next


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now